Click for best price
Neurodegenerative Drugs Market Size, Share 2022
Market Analysis and Insights: Global Neurodegenerative Drugs Market
The global Neurodegenerative Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Drugs market.
Global Neurodegenerative Drugs Scope and Market Size
Neurodegenerative Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Neurodegenerative Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Segment by Application
Parkinson?s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer?s Disease
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Neurodegenerative Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Neurodegenerative Drugs, with price, sales, revenue, and global market share of Neurodegenerative Drugs from 2019 to 2022.
Chapter 3, the Neurodegenerative Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurodegenerative Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Neurodegenerative Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurodegenerative Drugs.
Chapter 13, 14, and 15, to describe Neurodegenerative Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Neurodegenerative Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Neurodegenerative Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
116 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Neurodegenerative Drugs Product Introduction
1.2 Global Neurodegenerative Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Neurodegenerative Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Neurodegenerative Drugs Sales in Volume for the Year 2017-2028
1.3 United States Neurodegenerative Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Neurodegenerative Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Neurodegenerative Drugs Sales in Volume for the Year 2017-2028
1.4 Neurodegenerative Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Neurodegenerative Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Neurodegenerative Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Neurodegenerative Drugs Market Dynamics
1.5.1 Neurodegenerative Drugs Industry Trends
1.5.2 Neurodegenerative Drugs Market Drivers
1.5.3 Neurodegenerative Drugs Market Challenges
1.5.4 Neurodegenerative Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Neurodegenerative Drugs Market Segment by Type
2.1.1 NMDA
2.1.2 SSRIs
2.1.3 Dopamine Inhibitors
2.2 Global Neurodegenerative Drugs Market Size by Type
2.2.1 Global Neurodegenerative Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Neurodegenerative Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Neurodegenerative Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Neurodegenerative Drugs Market Size by Type
2.3.1 United States Neurodegenerative Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Neurodegenerative Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Neurodegenerative Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Neurodegenerative Drugs Market Segment by Application
3.1.1 Parkinson?s Disease
3.1.2 Huntington Disease
3.1.3 Amyotrophic Lateral Sclerosis
3.1.4 Alzheimer?s Disease
3.2 Global Neurodegenerative Drugs Market Size by Application
3.2.1 Global Neurodegenerative Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Neurodegenerative Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Neurodegenerative Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Neurodegenerative Drugs Market Size by Application
3.3.1 United States Neurodegenerative Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Neurodegenerative Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Neurodegenerative Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Neurodegenerative Drugs Competitor Landscape by Company
4.1 Global Neurodegenerative Drugs Market Size by Company
4.1.1 Top Global Neurodegenerative Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Neurodegenerative Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Neurodegenerative Drugs Price by Manufacturer (2017-2022)
4.2 Global Neurodegenerative Drugs Concentration Ratio (CR)
4.2.1 Neurodegenerative Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Neurodegenerative Drugs in 2021
4.2.3 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Neurodegenerative Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Neurodegenerative Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Neurodegenerative Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Neurodegenerative Drugs Market Size by Company
4.5.1 Top Neurodegenerative Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Neurodegenerative Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Neurodegenerative Drugs Sales by Players (2020, 2021 & 2022)
5 Global Neurodegenerative Drugs Market Size by Region
5.1 Global Neurodegenerative Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Neurodegenerative Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Neurodegenerative Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Neurodegenerative Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Neurodegenerative Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Neurodegenerative Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Neurodegenerative Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Neurodegenerative Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Neurodegenerative Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Neurodegenerative Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Merck Serono
7.3.1 Merck Serono Corporation Information
7.3.2 Merck Serono Description and Business Overview
7.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Merck Serono Neurodegenerative Drugs Products Offered
7.3.5 Merck Serono Recent Development
7.4 Biogen Idec
7.4.1 Biogen Idec Corporation Information
7.4.2 Biogen Idec Description and Business Overview
7.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
7.4.5 Biogen Idec Recent Development
7.5 TEVA
7.5.1 TEVA Corporation Information
7.5.2 TEVA Description and Business Overview
7.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 TEVA Neurodegenerative Drugs Products Offered
7.5.5 TEVA Recent Development
7.6 UCB
7.6.1 UCB Corporation Information
7.6.2 UCB Description and Business Overview
7.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 UCB Neurodegenerative Drugs Products Offered
7.6.5 UCB Recent Development
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Corporation Information
7.7.2 Boehringer Ingelheim Description and Business Overview
7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
7.7.5 Boehringer Ingelheim Recent Development
7.8 Sanofi
7.8.1 Sanofi Corporation Information
7.8.2 Sanofi Description and Business Overview
7.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Sanofi Neurodegenerative Drugs Products Offered
7.8.5 Sanofi Recent Development
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Corporation Information
7.9.2 GlaxoSmithKline Description and Business Overview
7.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
7.9.5 GlaxoSmithKline Recent Development
7.10 Livzon Pharmaceutical
7.10.1 Livzon Pharmaceutical Corporation Information
7.10.2 Livzon Pharmaceutical Description and Business Overview
7.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products Offered
7.10.5 Livzon Pharmaceutical Recent Development
7.11 Haisco Pharmaceutical
7.11.1 Haisco Pharmaceutical Corporation Information
7.11.2 Haisco Pharmaceutical Description and Business Overview
7.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Products Offered
7.11.5 Haisco Pharmaceutical Recent Development
7.12 Jingxin Pharmaceutical
7.12.1 Jingxin Pharmaceutical Corporation Information
7.12.2 Jingxin Pharmaceutical Description and Business Overview
7.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Jingxin Pharmaceutical Products Offered
7.12.5 Jingxin Pharmaceutical Recent Development
7.13 Dongcheng Biochemicals
7.13.1 Dongcheng Biochemicals Corporation Information
7.13.2 Dongcheng Biochemicals Description and Business Overview
7.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Dongcheng Biochemicals Products Offered
7.13.5 Dongcheng Biochemicals Recent Development
7.14 Hisun Pharmaceutical
7.14.1 Hisun Pharmaceutical Corporation Information
7.14.2 Hisun Pharmaceutical Description and Business Overview
7.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Hisun Pharmaceutical Products Offered
7.14.5 Hisun Pharmaceutical Recent Development
7.15 Luye Pharma
7.15.1 Luye Pharma Corporation Information
7.15.2 Luye Pharma Description and Business Overview
7.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Luye Pharma Products Offered
7.15.5 Luye Pharma Recent Development
7.16 Ark Pharmaceutical
7.16.1 Ark Pharmaceutical Corporation Information
7.16.2 Ark Pharmaceutical Description and Business Overview
7.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Ark Pharmaceutical Products Offered
7.16.5 Ark Pharmaceutical Recent Development
7.17 Kanghong Pharmaceutical
7.17.1 Kanghong Pharmaceutical Corporation Information
7.17.2 Kanghong Pharmaceutical Description and Business Overview
7.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Kanghong Pharmaceutical Products Offered
7.17.5 Kanghong Pharmaceutical Recent Development
7.18 Huahai Pharmaceutical
7.18.1 Huahai Pharmaceutical Corporation Information
7.18.2 Huahai Pharmaceutical Description and Business Overview
7.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Huahai Pharmaceutical Products Offered
7.18.5 Huahai Pharmaceutical Recent Development
7.19 BORA PHARMACEUTICALS
7.19.1 BORA PHARMACEUTICALS Corporation Information
7.19.2 BORA PHARMACEUTICALS Description and Business Overview
7.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 BORA PHARMACEUTICALS Products Offered
7.19.5 BORA PHARMACEUTICALS Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Neurodegenerative Drugs Industry Chain Analysis
8.2 Neurodegenerative Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Neurodegenerative Drugs Distributors
8.3 Neurodegenerative Drugs Production Mode & Process
8.4 Neurodegenerative Drugs Sales and Marketing
8.4.1 Neurodegenerative Drugs Sales Channels
8.4.2 Neurodegenerative Drugs Distributors
8.5 Neurodegenerative Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Neurodegenerative Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Neurodegenerative Drugs Market Trends
Table 3. Neurodegenerative Drugs Market Drivers
Table 4. Neurodegenerative Drugs Market Challenges
Table 5. Neurodegenerative Drugs Market Restraints
Table 6. Global Neurodegenerative Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Neurodegenerative Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Neurodegenerative Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Neurodegenerative Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Neurodegenerative Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Neurodegenerative Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Neurodegenerative Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Neurodegenerative Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Neurodegenerative Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Neurodegenerative Drugs Price by Manufacturer (2017-2022) & (US$/Unit)
Table 16. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2021)
Table 18. Top Players of Neurodegenerative Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Neurodegenerative Drugs Product Type
Table 20. Date of International Manufacturers Enter into Neurodegenerative Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Neurodegenerative Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Neurodegenerative Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Neurodegenerative Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Neurodegenerative Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Neurodegenerative Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Neurodegenerative Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Neurodegenerative Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Neurodegenerative Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Neurodegenerative Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Neurodegenerative Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Neurodegenerative Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Neurodegenerative Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Neurodegenerative Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Neurodegenerative Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Neurodegenerative Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Neurodegenerative Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Neurodegenerative Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Neurodegenerative Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Neurodegenerative Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Novartis Corporation Information
Table 43. Novartis Description and Business Overview
Table 44. Novartis Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 45. Novartis Neurodegenerative Drugs Product
Table 46. Novartis Recent Development
Table 47. Pfizer Corporation Information
Table 48. Pfizer Description and Business Overview
Table 49. Pfizer Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 50. Pfizer Product
Table 51. Pfizer Recent Development
Table 52. Merck Serono Corporation Information
Table 53. Merck Serono Description and Business Overview
Table 54. Merck Serono Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 55. Merck Serono Product
Table 56. Merck Serono Recent Development
Table 57. Biogen Idec Corporation Information
Table 58. Biogen Idec Description and Business Overview
Table 59. Biogen Idec Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 60. Biogen Idec Product
Table 61. Biogen Idec Recent Development
Table 62. TEVA Corporation Information
Table 63. TEVA Description and Business Overview
Table 64. TEVA Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 65. TEVA Product
Table 66. TEVA Recent Development
Table 67. UCB Corporation Information
Table 68. UCB Description and Business Overview
Table 69. UCB Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 70. UCB Product
Table 71. UCB Recent Development
Table 72. Boehringer Ingelheim Corporation Information
Table 73. Boehringer Ingelheim Description and Business Overview
Table 74. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 75. Boehringer Ingelheim Product
Table 76. Boehringer Ingelheim Recent Development
Table 77. Sanofi Corporation Information
Table 78. Sanofi Description and Business Overview
Table 79. Sanofi Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 80. Sanofi Product
Table 81. Sanofi Recent Development
Table 82. GlaxoSmithKline Corporation Information
Table 83. GlaxoSmithKline Description and Business Overview
Table 84. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 85. GlaxoSmithKline Product
Table 86. GlaxoSmithKline Recent Development
Table 87. Livzon Pharmaceutical Corporation Information
Table 88. Livzon Pharmaceutical Description and Business Overview
Table 89. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 90. Livzon Pharmaceutical Product
Table 91. Livzon Pharmaceutical Recent Development
Table 92. Haisco Pharmaceutical Corporation Information
Table 93. Haisco Pharmaceutical Description and Business Overview
Table 94. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 95. Haisco Pharmaceutical Product
Table 96. Haisco Pharmaceutical Recent Development
Table 97. Jingxin Pharmaceutical Corporation Information
Table 98. Jingxin Pharmaceutical Description and Business Overview
Table 99. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 100. Jingxin Pharmaceutical Product
Table 101. Jingxin Pharmaceutical Recent Development
Table 102. Dongcheng Biochemicals Corporation Information
Table 103. Dongcheng Biochemicals Description and Business Overview
Table 104. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 105. Dongcheng Biochemicals Product
Table 106. Dongcheng Biochemicals Recent Development
Table 107. Hisun Pharmaceutical Corporation Information
Table 108. Hisun Pharmaceutical Description and Business Overview
Table 109. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Hisun Pharmaceutical Product
Table 111. Hisun Pharmaceutical Recent Development
Table 112. Luye Pharma Corporation Information
Table 113. Luye Pharma Description and Business Overview
Table 114. Luye Pharma Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Luye Pharma Product
Table 116. Luye Pharma Recent Development
Table 117. Ark Pharmaceutical Corporation Information
Table 118. Ark Pharmaceutical Description and Business Overview
Table 119. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. Ark Pharmaceutical Product
Table 121. Ark Pharmaceutical Recent Development
Table 122. Kanghong Pharmaceutical Corporation Information
Table 123. Kanghong Pharmaceutical Description and Business Overview
Table 124. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Kanghong Pharmaceutical Product
Table 126. Kanghong Pharmaceutical Recent Development
Table 127. Huahai Pharmaceutical Corporation Information
Table 128. Huahai Pharmaceutical Description and Business Overview
Table 129. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Huahai Pharmaceutical Product
Table 131. Huahai Pharmaceutical Recent Development
Table 132. BORA PHARMACEUTICALS Corporation Information
Table 133. BORA PHARMACEUTICALS Description and Business Overview
Table 134. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. BORA PHARMACEUTICALS Product
Table 136. BORA PHARMACEUTICALS Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Neurodegenerative Drugs Customers List
Table 140. Neurodegenerative Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Global Neurodegenerative Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Neurodegenerative Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Neurodegenerative Drugs Sales 2017-2028 (K Units)
Figure 5. United States Neurodegenerative Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Neurodegenerative Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Neurodegenerative Drugs Sales 2017-2028 (K Units)
Figure 8. United States Neurodegenerative Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Neurodegenerative Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Neurodegenerative Drugs Report Years Considered
Figure 11. Product Picture of NMDA
Figure 12. Product Picture of SSRIs
Figure 13. Product Picture of Dopamine Inhibitors
Figure 14. Global Neurodegenerative Drugs Market Share by Type in 2022 & 2028
Figure 15. Global Neurodegenerative Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Neurodegenerative Drugs Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Neurodegenerative Drugs Sales by Type (2017-2028) & (K Units)
Figure 18. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Neurodegenerative Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 20. United States Neurodegenerative Drugs Market Share by Type in 2022 & 2028
Figure 21. United States Neurodegenerative Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Neurodegenerative Drugs Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Neurodegenerative Drugs Sales by Type (2017-2028) & (K Units)
Figure 24. United States Neurodegenerative Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Neurodegenerative Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 26. Product Picture of Parkinson?s Disease
Figure 27. Product Picture of Huntington Disease
Figure 28. Product Picture of Amyotrophic Lateral Sclerosis
Figure 29. Product Picture of Alzheimer?s Disease
Figure 30. Global Neurodegenerative Drugs Market Share by Application in 2022 & 2028
Figure 31. Global Neurodegenerative Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Neurodegenerative Drugs Sales by Application (2017-2028) & (K Units)
Figure 34. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Neurodegenerative Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 36. United States Neurodegenerative Drugs Market Share by Application in 2022 & 2028
Figure 37. United States Neurodegenerative Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Neurodegenerative Drugs Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Neurodegenerative Drugs Sales by Application (2017-2028) & (K Units)
Figure 40. United States Neurodegenerative Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Neurodegenerative Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 42. North America Neurodegenerative Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 43. North America Neurodegenerative Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. United States Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Neurodegenerative Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 47. Europe Neurodegenerative Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Neurodegenerative Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 54. Asia-Pacific Neurodegenerative Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. China Taiwan Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Latin America Neurodegenerative Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 65. Latin America Neurodegenerative Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 66. Mexico Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Brazil Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Argentina Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Middle East & Africa Neurodegenerative Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 70. Middle East & Africa Neurodegenerative Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 71. Turkey Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Saudi Arabia Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. UAE Neurodegenerative Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Neurodegenerative Drugs Value Chain
Figure 75. Neurodegenerative Drugs Production Process
Figure 76. Channels of Distribution
Figure 77. Distributors Profiles
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
